Ensysce Biosciences Inc
NASDAQ:ENSC
Intrinsic Value
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
ENSC
stock under the Base Case scenario is
138.06
USD.
Compared to the current market price of 0.58 USD,
Ensysce Biosciences Inc
is
Undervalued by 100%.
Ensysce Biosciences Inc's market capitalization is 4.3m USD.
ENSC stock price is 0.58 USD.
ENSC stock price (0.58 USD) is 100% less than its Intrinsic Value (138.06 USD).
ENSC stock price (0.58 USD) is 99% less than its Relative Value (71.12 USD). Open Relative Valuation
ENSC.
ENSC's Revenue has dropped by 11% over the past 12 months.
ENSC's long-term liabilties (3m USD) exceed its long-term assets (3m USD).
ENSC's ROE (Return on Equity) has significantly increased in the last 3 years from 65% to 528%.
ENSC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -3% to 4 748%.
ENSC's short-term liabilties (3m USD) exceed its short-term assets (2m USD).
ENSC has negative Operating Income for the last twelve months.
ENSC has negative Net Income for the last twelve months.
ENSC's ROE (Return on Equity) for the past 12 months is very high and is equal to 528%.
ENSC's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 4 748%.
ENSC's Revenue is forecast to grow at a rate of 201% per year over the next 3 years.
ENSC has negative Free Cash Flow for the last twelve months.
ENSC has negative three-year average ROE (Return on Equity): -395%. The company is not efficient at transforming stockholders' equity into net income.
ENSC has very high three-year average ROIC (Return on Invested Capital): 558%. The company is very efficient at using invested capital to generate operating income.
ENSC's D/E (Debt to Equity) is very low and is equal to 0.
ENSC's Altman Z-Score is very low and is equal to -74.5.
Fundamental Analysis
Ensysce Biosciences Inc
Balance Sheet Decomposition
Ensysce Biosciences Inc
| Current Assets | 2.3m |
| Cash & Short-Term Investments | 1.1m |
| Receivables | 97.6k |
| Other Current Assets | 1.1m |
| Non-Current Assets | 419.2k |
| Other Non-Current Assets | 419.2k |
| Current Liabilities | 3.3m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 542.3k |
| Other Current Liabilities | 854.7k |
| Non-Current Liabilities | -302k |
| Other Non-Current Liabilities | -302k |
Earnings Waterfall
Ensysce Biosciences Inc
|
Revenue
|
2.2m
USD
|
|
Operating Expenses
|
-12.9m
USD
|
|
Operating Income
|
-10.7m
USD
|
|
Other Expenses
|
92.2k
USD
|
|
Net Income
|
-10.6m
USD
|
Free Cash Flow Analysis
Ensysce Biosciences Inc
What is Free Cash Flow?
ENSC Profitability Score
Profitability Due Diligence
Ensysce Biosciences Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Ensysce Biosciences Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
ENSC Solvency Score
Solvency Due Diligence
Ensysce Biosciences Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Ensysce Biosciences Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENSC Price Targets Summary
Ensysce Biosciences Inc
Ownership
ENSC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ENSC Price
Ensysce Biosciences Inc
| Average Annual Return | -35.61% |
| Standard Deviation of Annual Returns | 55.79% |
| Max Drawdown | -100% |
| Market Capitalization | 4.3m USD |
| Shares Outstanding | 7 329 170 |
| Percentage of Shares Shorted | 0.24% |
Company Profile
Ensysce Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.
You don't have any saved screeners yet
